Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Helixbind Inc. is currently overseeing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are distributed among 2 distinct examiners, which indicates that each matter is being handled by a different individual at the patent office. The data also reflects that the prosecution is occurring across 2 distinct art units, showing a division in the technical classification of the filings.
The busiest examiner for this portfolio is WOOLWINE, SAMUEL C, who is currently managing 1 busiest examiner pending office action. This 1 busiest examiner pending office action is 1 of the 2 pending office actions currently active for the company. The use of 2 distinct examiners across 2 distinct art units suggests that the company's Biotechnology & Pharmaceuticals applications are subject to different examination perspectives.
For practitioners, the presence of 2 distinct art units means that the prosecution strategy must account for the specific practices of each unit. Since WOOLWINE, SAMUEL C is responsible for 1 busiest examiner pending office action, the company must also manage the requirements of the other examiner involved. This distribution across 2 distinct examiners prevents a total concentration of the portfolio's outcomes under a single person.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.4% |
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17370819 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS USING GAMMA PEPTIDE NUCLEIC ACIDS | GROSS, CHRISTOPHER M | 22d overdue |
| 18351061 | METHODS AND DEVICES FOR ULTRASENSITIVE DIRECT DETECTION OF MICROORGANISMS | WOOLWINE, SAMUEL C | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18351061 | METHODS AND DEVICES FOR ULTRASENSITIVE DIRECT DETECTION OF MICROORGANISMS | WOOLWINE, SAMUEL C | 1681 | §112 | Non-Final OA | 3d overdue | Pending | Jul 12, 2023 |
| 17370819 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS USING GAMMA PEPTIDE NUCLEIC ACIDS | GROSS, CHRISTOPHER M | 1684 | §103 | Final Rejection | 22d overdue | Pending | Jul 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial